Amgen (AMGN) Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer

Go back to Amgen (AMGN) Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer